Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis.

Li A, Su X, Hu S, Wang Y

Diabetes research and clinical practice5 Mar 2023Cited by 39 (Europe PMC)

PMID36871874DOI10.1016/j.diabres.2023.110605PepBankPUB-36871874

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, oral semaglutide 7 mg and 14 mg both significantly reduced body weight in a meta-analysis.
In plain wordsIn pooled trials of adults with type 2 diabetes, both oral semaglutide doses lowered body weight.
Peptide
Semaglutide
Outcome
DecreaseBody weight change
Study
n = 9,821
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
7 and 14 mg · oralAs given in this study (human).
Source sentences
Summary
Both doses of semaglutide could significantly reduce body weight.
1 context sentence(design, population, supporting numbers)
Summary · context
Search several databases for randomized controlled trials (RCTs) of oral semaglutide in patients with T2DM from inception through May 31, 2021.
Report a problemFND-3687187405
02HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, oral semaglutide 7 mg reduced HbA1c more than placebo in a meta-analysis.
In plain wordsIn pooled trials of adults with type 2 diabetes, oral semaglutide 7 mg lowered HbA1c more than placebo.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change vs placebo, 7 mg
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
7 mg · oralAs given in this study (human).
Measurements
HbA1c reduction
1.06%
7 mg vs placebo
Source sentences
Summary
Compared with placebo, semaglutide 7 and 14 mg reduced HbA1c by 1.06% (95% CI, 0.81-1.30) and 1.10% (95% CI, 0.88-1.31), respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Search several databases for randomized controlled trials (RCTs) of oral semaglutide in patients with T2DM from inception through May 31, 2021.
Report a problemFND-3687187401
03HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, oral semaglutide 14 mg reduced HbA1c more than placebo in a meta-analysis.
In plain wordsIn pooled trials of adults with type 2 diabetes, oral semaglutide 14 mg lowered HbA1c more than placebo.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change vs placebo, 14 mg
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
14 mg · oralAs given in this study (human).
Measurements
HbA1c reduction
1.1%
14 mg vs placebo
Source sentences
Summary
Compared with placebo, semaglutide 7 and 14 mg reduced HbA1c by 1.06% (95% CI, 0.81-1.30) and 1.10% (95% CI, 0.88-1.31), respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Search several databases for randomized controlled trials (RCTs) of oral semaglutide in patients with T2DM from inception through May 31, 2021.
Report a problemFND-3687187402
04HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, oral semaglutide 7 mg reduced HbA1c more than other antidiabetic agents in a meta-analysis.
In plain wordsIn pooled trials of adults with type 2 diabetes, oral semaglutide 7 mg lowered HbA1c more than other diabetes drugs.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change vs other antidiabetic agents, 7 mg
Study
n: not reported in source
Comparator
Other antidiabetic agents
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
7 mg · oralAs given in this study (human).
Measurements
HbA1c reduction
0.26%
7 mg vs other antidiabetic agents
Source sentences
Summary
While in comparison with other antidiabetic agents, semaglutide 7 and 14 mg reduced HbA1c by 0.26% (95% CI, 0.15-0.38) and 0.38% (95%CI, 0.31-0.45).
1 context sentence(design, population, supporting numbers)
Summary · context
Search several databases for randomized controlled trials (RCTs) of oral semaglutide in patients with T2DM from inception through May 31, 2021.
Report a problemFND-3687187403
05HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, oral semaglutide 14 mg reduced HbA1c more than other antidiabetic agents in a meta-analysis.
In plain wordsIn pooled trials of adults with type 2 diabetes, oral semaglutide 14 mg lowered HbA1c more than other diabetes drugs.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change vs other antidiabetic agents, 14 mg
Study
n: not reported in source
Comparator
Other antidiabetic agents
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
14 mg · oralAs given in this study (human).
Measurements
HbA1c reduction
0.38%
14 mg vs other antidiabetic agents
Source sentences
Summary
While in comparison with other antidiabetic agents, semaglutide 7 and 14 mg reduced HbA1c by 0.26% (95% CI, 0.15-0.38) and 0.38% (95%CI, 0.31-0.45).
1 context sentence(design, population, supporting numbers)
Summary · context
Search several databases for randomized controlled trials (RCTs) of oral semaglutide in patients with T2DM from inception through May 31, 2021.
Report a problemFND-3687187404
06HumanSystematic reviewSafety outcome
In adults with type 2 diabetes, oral semaglutide 14 mg increased the incidence of medication discontinuation in a meta-analysis.
In plain wordsIn pooled trials of adults with type 2 diabetes, more people stopped taking oral semaglutide 14 mg.
Peptide
Semaglutide
Outcome
IncreaseMedication discontinuation, 14 mg
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
14 mg · oralAs given in this study (human).
Source sentences
Summary
Semaglutide 14 mg did increase the incidence of medication discontinuation and gastrointestinal events (nausea, vomiting and diarrhea).
1 context sentence(design, population, supporting numbers)
Summary · context
Search several databases for randomized controlled trials (RCTs) of oral semaglutide in patients with T2DM from inception through May 31, 2021.
Report a problemFND-3687187406
07HumanSystematic reviewSafety outcome
In adults with type 2 diabetes, oral semaglutide 14 mg increased the incidence of nausea, vomiting and diarrhea in a meta-analysis.
In plain wordsIn pooled trials of adults with type 2 diabetes, oral semaglutide 14 mg caused more nausea, vomiting and diarrhea.
Peptide
Semaglutide
Outcome
IncreaseGastrointestinal events (nausea, vomiting, diarrhea), 14 mg
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
14 mg · oralAs given in this study (human).
Source sentences
Summary
Semaglutide 14 mg did increase the incidence of medication discontinuation and gastrointestinal events (nausea, vomiting and diarrhea).
1 context sentence(design, population, supporting numbers)
Summary · context
Search several databases for randomized controlled trials (RCTs) of oral semaglutide in patients with T2DM from inception through May 31, 2021.
Report a problemFND-3687187407

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase 2NCT06072963

COMMETS- Combination MCI Metabolic Syndrome

Rutgers, The State University of New Jerseyn = 8030 Jan 2024 to est. 1 Dec 2028

Alzheimer Disease · Mild Cognitive Impairment · Metabolic Syndrome

Trial page ClinicalTrials.govUpdated 27 Jul 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.